Peptide Therapeutics In Metabolic Disorders Market 2024 Product Type, Market price, Production Area, Regions, Development Trend, Manufacturing Base Distribution, and Forecast to 2031

Market Overview:

Peptide therapeutics in metabolic disorders are used for the treatment of various metabolic disorders like diabetes, obesity, kidney disorders etc. These peptides are short chains of amino acids that play important metabolic roles in the body.

Market Dynamics:

The peptide therapeutics in metabolic disorders market is expected to grow rapidly during the forecast period owing to the rising prevalence of metabolic disorders and increasing research activities in the field of peptide therapeutics. According to WHO, globally 420 million people suffer from diabetes and 1.5 million deaths are directly caused by diabetes each year. The growing burden of diabetes and other metabolic disorders is propelling the demand for advanced treatment options like peptide therapeutics across the globe. Moreover, various research studies proving efficacies of peptides in controlling metabolic conditions like obesity, hyperglycemia are further supporting the market growth. For instance, in 2018 a study published in Nature demonstrated the effects of a peptide in reducing body weight and hyperglycemia in diabetic mice.

Get a Sample Copy Of The Report, Covering TOC and Regional Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2003

Major Keyplayers Included in the Report:

AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.

Major Market Driver: Growing Prevalence of Metabolic Disorders Such as Diabetes and Obesity Globally

The global peptide therapeutics in metabolic disorders market is primarily driven by the growing prevalence of metabolic disorders like diabetes and obesity across the world. According to the World Health Organization (WHO), the global prevalence of diabetes has nearly quadrupled between 1980 and 2014. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Additionally, obesity rates have also increased three folds since 1975. Over 650 million adults worldwide are currently obese. With lifestyle changes leading more people gaining excessive weight and lack of physical activities becoming a norm, metabolic disorders have emerged as a major health issue. Peptide therapeutics offer tailored treatment options for patients suffering from these conditions compared to conventional drugs. This fuels the demand for peptide drugs in the metabolic disorders market.

Significant Market Driver: Increasing Research into Peptide Drug Development for Metabolic Conditions

Another key driver for market growth is the increasing research funding and activities focused on developing novel peptide therapeutics for metabolic disorders. Several biopharmaceutical companies and research institutions are investing heavily in R&D to discover and design peptides that can effectively treat diabetes, obesity and other such chronic conditions. There is a growing understanding that endocrinological agents may prove to be more useful alternatives than small-molecule drugs for conditions involving hormonal regulation and metabolism. This has accelerated research into peptide mimetics that can mimic natural metabolic hormones like GLP-1, GLP-2, amylin, oxyntomodulin etc. Ongoing clinical trials evaluating the efficacy and safety of various metabolic regulating peptides in controlling blood sugar levels, weight management and insulin resistance are driving the use of peptide therapy in metabolic space.

Major Market Restrain: High Development Cost of Peptide Drugs

One of the key challenges faced by players in the peptide therapeutics in metabolic disorders market is the high cost associated with research, development and production of peptide drugs. Unlike conventional small molecule drugs, peptides are large and complex biomolecules to manufacture. Specialized techniques like solid phase peptide synthesis and recombinant DNA technology are required, making the development process lengthy and capital intensive. Ensuring quality, stability and safety of peptide products also adds to manufacturing expenses. High failure rates during clinical trials further inflate development costs. This makes peptide drugs less affordable for patients compared to traditional medications. The high price of peptide formulations acts as a major restrain restricting their widespread adoption, especially in developing nations with budget constraints on healthcare spending.

Significant Market Opportunity: Emerging Economies with Growing Disease Burden

The peptide therapeutics in metabolic disorders market possesses significant growth opportunities in emerging economies across Asia Pacific, Latin America, Middle East and Africa. These regions are facing rapid economic development as well as epidemiological transition characterized by rising obesity, cardiovascular issues and diabetes prevalence due to changing dietary patterns and lifestyle shifts. For example, China and India have established themselves as the global diabetes capitals. The metabolic disease landscape in developing countries presents a lucrative business avenue for manufacturers to tap into. Increasing healthcare investments by local governments as well as higher patient affordability driven by economic growth are encouraging more patients to opt for specialized peptide treatments. Key players are strategizing market entry into emerging markets by developing low-cost peptide formulations and setting up local manufacturing capacities.

Important Market Trend: Partnerships for Combination Therapies

A notable trend being observed in the peptide therapeutics in metabolic disorders market is the rising number of strategic collaborations between developers of peptide drugs and manufacturers of other drug classes. Companies are exploring opportunities to combine peptides with small molecules, monoclonal antibodies or other biologics to develop multi-drug regimens capable of synergistically addressing metabolic conditions. For instance, collaborations to develop fixed-dose combination products comprising GLP-1 agonists and SGLT-2 inhibitors to provide superior glycemic control and weight management for diabetes. Similarly, partnerships for combining appetite-regulating peptides with anti-obesity drugs. Such combination therapies have demonstrated enhanced clinical efficacy over monotherapies. They are also convenient for patients to adhere to multiple medications. This growing focus on combination strategies through partnerships reflects in the peptide therapeutics market evolution.

Purchase This Premium Report With Up To 25% OFF @ https://www.coherentmarketinsights.com/insight/buy-now/2003

Table of Contents with Major Points:

Executive Summary

Introduction
Key Findings
Recommendations
Definitions and Assumptions

Market Overview

Definition of Peptide Therapeutics In Metabolic Disorders Market
Market Dynamics
Drivers
Restraints
Opportunities
Trends and Developments

Key Insights

Key Emerging Trends
Key Developments Mergers and Acquisition
New Product Launches and Collaboration
Partnership and Joint Venture
Latest Technological Advancements
Insights on Regulatory Scenario
Porters Five Forces Analysis

Qualitative Insights Impact of COVID-19 on Global Peptide Therapeutics In Metabolic Disorders Market

Supply Chain Challenges
Steps taken by Government/Companies to overcome this impact
Potential opportunities due to COVID-19 outbreak
Conclusion

Appendix

Data Sources
Abbreviations
Disclaimer
TOC Continued…!

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/2003

Why Choose Coherent Market Insights?

☛ Identified business opportunities - Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services.

☛ A clear understanding of your customers - A market report gives company's marketing department an in-depth picture about customers' needs and wants. This knowledge can be used to improve products, prices, and advertising.

☛ Clear data-driven insights - Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact:

Mr Shah

Coherent Market Insights

533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This release was published on openPR.